Entering text into the input field will update the search result below

GDTC CytoMed Therapeutics Limited
Stock Price & Overview

$3.52-0.17 (-4.57%)2:24 PM 12/01/23
NASDAQ | $USD | Post-Market: $3.47 -0.05 (-1.46%) 4:00 PM


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

Ratings Summary

SA Analysts
Wall Street

See GDTC ratings with Premium.

People Also Follow

Company Profile

CytoMed Therapeutics Limited logo
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
  • 1 Commonwealth Lane, No. 08-22
  • Singapore, 149544
  • Singapore
Phone Number
65 6250 7738
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.